A Long-Term Extension Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Patients With Graves' Disease

Conditions

Graves’ Disease

Brief summary

Percentage of Group A Participants who remain euthyroid, off ATD, and off IMVT-1402 [Time Frame: At Week 52]

Detailed description

Percentage of Group A Participants who are euthyroid and off ATD [Time Frame: At Week 26], Percentage of Group A Participants who are euthyroid and off ATD [Time Frame: Up to Week 52], Percentage of Group A Participants who are euthyroid, off ATD, and off IMVT-1402 [Time Frame: Up to Week 52], Time to earliest date of euthyroidism, off ATD, and off IMVT-1402 to the earliest date of confirmed relapse in Group A Participants [Time Frame: Up to Week 52], Percentage of Group B Participants who remain euthyroid, off ATD, and off IMVT-1402 [Time Frame: Up to Week 52], Percentage of Group B Participants who remain euthyroid, off ATD, and off IMVT-1402 [Time Frame: At Week 52], Time from Week 0 to the earliest date of confirmed relapse in Group B Participants [Time Frame: Up to Week 52], Percentage of Group C Participants who remain euthyroid, off ATD, and off IMVT-1402 [Time Frame: Up to Week 52], Percentage of Group C Participants who remain euthyroid, off ATD, and off IMVT-1402 [Time Frame: At Week 52], Time From Week 0 to the earliest date of confirmed relapse in Group C Participants [Time Frame: Up to Week 52], Percentage of Group A Participants who are euthyroid, off ATD, and seronegative for TRAb [Time Frame: At Week 26], Percentage of Group A Participants who are euthyroid, off ATD, and seronegative for TRAb [Time Frame: Up to Week 52]

Related papers

No related papers found yet.

Interventions

DRUGIMVT-1402

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Percentage of Group A Participants who remain euthyroid, off ATD, and off IMVT-1402 [Time Frame: At Week 52]	—

Secondary

Measure	Time frame
Percentage of Group A Participants who are euthyroid and off ATD [Time Frame: At Week 26], Percentage of Group A Participants who are euthyroid and off ATD [Time Frame: Up to Week 52], Percentage of Group A Participants who are euthyroid, off ATD, and off IMVT-1402 [Time Frame: Up to Week 52], Time to earliest date of euthyroidism, off ATD, and off IMVT-1402 to the earliest date of confirmed relapse in Group A Participants [Time Frame: Up to Week 52], Percentage of Group B Participants who remain euthyroid, off ATD, and off IMVT-1402 [Time Frame: Up to Week 52], Percentage of Group B Participants who remain euthyroid, off ATD, and off IMVT-1402 [Time Frame: At Week 52], Time from Week 0 to the earliest date of confirmed relapse in Group B Participants [Time Frame: Up to Week 52], Percentage of Group C Participants who remain euthyroid, off ATD, and off IMVT-1402 [Time Frame: Up to Week 52], Percentage of Group C Participants who remain euthyroid, off ATD, and off IMVT-1402 [Time Fram	—

Measure

Time frame

Percentage of Group A Participants who are euthyroid and off ATD [Time Frame: At Week 26], Percentage of Group A Participants who are euthyroid and off ATD [Time Frame: Up to Week 52], Percentage of Group A Participants who are euthyroid, off ATD, and off IMVT-1402 [Time Frame: Up to Week 52], Time to earliest date of euthyroidism, off ATD, and off IMVT-1402 to the earliest date of confirmed relapse in Group A Participants [Time Frame: Up to Week 52], Percentage of Group B Participants who remain euthyroid, off ATD, and off IMVT-1402 [Time Frame: Up to Week 52], Percentage of Group B Participants who remain euthyroid, off ATD, and off IMVT-1402 [Time Frame: At Week 52], Time from Week 0 to the earliest date of confirmed relapse in Group B Participants [Time Frame: Up to Week 52], Percentage of Group C Participants who remain euthyroid, off ATD, and off IMVT-1402 [Time Frame: Up to Week 52], Percentage of Group C Participants who remain euthyroid, off ATD, and off IMVT-1402 [Time Fram

—

Outcome results

None listed